. Author manuscript; available in PMC: 2011 Feb 17.

Published in final edited form as: Med Sci Sports Exerc. 2009 Aug;41(8):1597–1605. doi: 10.1249/MSS.0b013e31819f1f05

Table 1.

Tumor incidence, multiplicity, metastasis, and growth by experiment and treatment group.

	Experiment 1			p	Experiment 2
	CON-TREX (n=22)	TREX1 (n=20)	TREX2 (n=21)	p	CONWHL (n=21)	WHL (n=20)	p
No. mice with mammary carcinoma^*,^†	19/22 (86%)	19/20 (95%)	21/21 (100%)	0.26	16/21 (76%)	20/20 (100%)	0.05
No. mice with mammary carcinoma in >1 gland	5/19 (26%)	11/19 (58%)	14/21 (67%) ^‡	0.03	8/16 (50%)	16/20 (80%)	0.08
No. mice with mammary carcinoma metastasis in lung	6/19 (27%)	4/19 (21%)	5/21 (24%)	0.81	1/16 (6%)	6/20 (30%)	0.10
TUMOR GROWTH ^§	CON-TREX (n=19)	TREX1 (n=13)	TREX2 (n=17)	p	CONWHL (n=16)	WHL (n=20)	p

Time to 1.5 cm tumor (days; mean ± SE)	24.8 ± 1.1	13.8 ± 1.2^‡	19.5 ± 1.1	0.02	17.2 ± 1.1	22.5 ± 1.1	0.10

Other causes of sacrifice/death included: CON-TREX-adrenal pheochromocytoma, lipoma, end of study; TREX1-end of study; CON-WHL-T-cell lymphoma, sarcoma (n=3), end of study.

^†

Additional, non-mammary gland neoplasms: CON-TREX-sarcoma, clitoral gland carcinoma, rhabdomyosarcoma; TREX1-lymphoma.

^‡

p<0.05 vs. CON-TREX

^§

Includes only mice not censored in the survival analysis. Log transformed data used in the statistical analysis due to non-normal distribution; geometric means presented in table.